Loading…
← CockpitCompetitor Analysis › 6586.TWO CHO Pharma, Inc.Open in the cockpit ↗

CHO Pharma, Inc.6586.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Momentum neutral 52
Mkt cap
$488M
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$1.54M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-66.9 pp
WACC 9.5%
Hurdle
n/a
no reverse DCF
Close · TWDNT$80.40
1D-5.8%
1W+5.5%
1M-25.2%
3M-28.9%
6M+23.9%
YTD+186.1%
1Y+133.7%
ATR %10.3%
52w lowhigh45.9% off high

What CHO Pharma does

No business profile yet.

CHO Pharma at a glance

Size CHO Pharma (6586.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $488M, the 438th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$80.40 on 18 Nov 2026.

Performance Over six months the shares gained 23.9%, against -14.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd highest of 18 in its peer set.

Growth Revenue fell 46.9% over the last twelve months (peer median -4.0%); the operating margin is -17,694.3% (peer median -11.6%).

Valuation It trades at 8,281.1× enterprise value to sales against a peer median of 7.5× (most expensive of 14).

Capital Return on invested capital runs 66.9 points below its cost of capital (9.5% WACC).

Relative performance

10015020021 May 202621 Aug 202618 Nov 20266586.TWO 122Peer median 84
Six months, rebased to 100: CHO Pharma against the median of its 20 peers (local-currency closes).

CHO Pharma financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$1.71MNT$1.43MNT$3.58MNT$0NT$60,000
Revenue growth—-60%—-100%—
Gross profit-NT$22.6M-NT$25.5M-NT$23.8M-NT$28.3M-NT$35.8M
EBITDA-NT$278M-NT$299M-NT$223M-NT$241M-NT$315M
Net income-NT$268M-NT$290M-NT$212M-NT$306M-NT$338M
Free cash flow-NT$250M-NT$289M-NT$223M-NT$293M-NT$259M
Capital expenditureNT$10.9MNT$11.7MNT$5.49MNT$2.00MNT$9.40M
Total debtn/aNT$14.6MNT$28.9MNT$0NT$11.7M

Quarterly statements and history in the cockpit →

CHO Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%603255CBIO6882474147MNPRNGNE300858FENCVLAKMDADMACSTTK0419601151806586.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. CHO Pharma is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×2,500×5,000×7,500×6032556882474147300858FENCVLA11518065896586.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CHO Pharma is the large dot.

CHO Pharma competitors and peer comparison

How CHO Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CHO Pharma against its 20 peers (data as of 18 Nov 2026)
Measure6586.TWOPeer medianRank in peer set
1-month return-25.2%-10.2%5th lowest of 21
6-month return+23.9%-14.1%3rd highest of 18
Distance from 52-week high-45.9%-44.8%11th highest of 21
Revenue growth (TTM)-46.9%-4.0%3rd lowest of 15
Operating margin-17,694.3%-11.6%lowest of 15
EV / Sales8,281.1×7.5×most expensive of 14
ROIC minus cost of capital-66.9 pp-5.7 pp2nd lowest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a

Questions

Which companies are CHO Pharma's closest peers?
The cockpit's peer set: Liaoning Dingjide Petrochemical (603255.SS), Crescent Biopharma (CBIO), Sinotherapeutics (688247.SS), TaiMed Biologics (4147.TWO), Monopar Therapeutics (MNPR), Neurogene (NGNE), Beijing Scitop Bio-Tech (300858.SZ), Fennec Pharmaceuticals (FENC).
Is CHO Pharma expensive compared with its peers?
On ev / sales it trades at 8,281.1× against a peer median of 7.5×, most expensive of 14 in its peer set.
How has CHO Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +23.9% against -14.1% for the median peer; over one year +133.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.